Kornimate/medical-research-clean huggingface dataset:
exploring long-term risks and sti prevalence in pre-exposure prophylaxis users in gironde, france

Conditions: HIV Infections; Sexually Transmitted Diseases

Summary: safer-prep investigates the long-term impact of pre-exposure prophylaxis (prep) on risky sexual behaviors and sexually transmitted infection (sti) prevalence among users in aquitaine. the study aims to compare sti rates over the last three months between individuals on prep for over a year and those on prep for less than a year. this retrospective observational research offers insights into the evolving dynamics of sexual health practices, informing future prep prescriptions and enhancing preventive strategies.

scientific rationale: the safer-prep study stems from the imperative to comprehend the intricate interplay between pre-exposure prophylaxis (prep) utilization and sexual health dynamics. amidst the increasing adoption of prep for hiv prevention, concerns arise regarding potential behavioral shifts and heightened risks for sexually transmitted infections (stis). the comprehensive investigation into these phenomena seeks to provide nuanced insights into the long-term implications of prep, contributing valuable data to public health initiatives and refining prevention strategies in the face of evolving sexual health landscapes. procedure: participants, comprising individuals on prep for over a year and those for less than a year, will be engaged through a observational approach. data will be collected via self-administered questionnaires during routine consultations for prep renewal in various medical settings, including hospitals and private practices. this comprehensive strategy enables a nuanced exploration of sexual behaviors and sti prevalence.

Eligibility criteria:
inclusion criteria: * aged over 18 years old; * participants using prep for at least 6 months ; * french-speaking, without comprehension disorders ; * being affiliated to health insurance ; * willing to participate and to sign informed consent. exclusion criteria: * individuals with known hiv positivity;

Keywords: pre-exposure prophylaxis hiv prevention sexually transmitted infections long-term effects behavioral trends
assessment of cmv-specific elispot assay for predicting cmv co-infection in patients with pneumocystitis pneumonia (ace-pcp)

Conditions: Non-HIV Patients With Pneumocystis Jiroveci Pneumonia

Summary: pcp (pneumocystis jiroveci pneumonia) is one of the important opportunistic infections in immunocompromised patients including hiv-infected patients, transplant recipients, and immunosuppressant users. about one third of non-hiv patients with pcp have the evidence of co-infection with cmv. in this difficult clinical situation, physicians have difficulty to decide on whether anti-cmv treament will help patients with any evidence of cmv co-infection. however, there is no objective test to differentiate true co-infection of cmv from innocent bystander of cmv in those with pcp. the investigators thus evaluate the usefulness of cmv-specific elispot assay in patients with pcp to differentiate true co-infection of cmv from inocent bystander of cmv. this findings may guide physicians to decide anti-cmv treatment in patients with pcp and cmv co-infection.

pcp (pneumocystis jiroveci pneumonia) is one of the important opportunistic infections in immunocompromised patients including hiv-infected patients, transplant recipients, and immunosuppressant users. about one third of non-hiv patients with pcp have the evidence of co-infection with cmv. in this difficult clinical situation, physicians have difficulty to decide on whether anti-cmv treament will help patients with any evidence of cmv co-infection. however, there is no objective test to differentiate true co-infection of cmv from innocent bystander of cmv in those with pcp. the investigators thus evaluate the usefulness of cmv-specific elispot assay in patients with pcp to differentiate true co-infection of cmv from inocent bystander of cmv. this findings may guide physicians to decide anti-cmv treatment in patients with pcp and cmv co-infection.

Eligibility criteria:
inclusion criteria: * diagnosis of pcp based on pcp immunohistochemistry or pcp pcr * age 16 or more * agree with written informed consent * wbc count 2000/ul or more exclusion criteria: * hiv infection

Keywords: pneumocystis jiroveci, cytomegalovirus, co-infection
effects of dual-task training in people with multiple sclerosis

Conditions: Multiple Sclerosis

Summary: the purpose of this study is to investigate the effects of dual task training on balance, gait, dual-task performance, cognitive function, fatigue and functional mobility in people with multiple sclerosis(ms).

eligible participants will be randomized to dual-task group or control group. dual-task group will receive 8 weeks of dual-task training twice a week and home exercise program. control group will receive only home exercise program for 8 weeks. each participant will be assessed before and after the 8 weeks of treatment.

Eligibility criteria:
inclusion criteria: * having a definitive diagnosis of ms according to the revised mcdonald criteria * having expanded disability status scale score between 0-5.5 * no relapse in the last 30 days * having a mini mental test score of 24 and above * being fluent in turkish language * no condition that prevents exercising exclusion criteria: * being pregnant * presence of a neuro-musculoskeletal disease other than multiple sclerosis * having received physiotherapy for balance and gait disorders in the last 3 months

Keywords: multiple sclerosis balance gait dual-task cognitive function functional mobility activities of daily living
a clinical trial on effectiveness and safety of hydrogen generator to treat dyspnea for the patients with tracheal stenosis: a randomized, double-blind and single-center clinical study

Conditions: Tracheal Stenosis

Summary: investigators aim to study the effectiveness and safety of inhaling hydrogen-oxygen which produced by a hydrogen generator with nebulizer to decreases inspiratory effort for the patients with tracheal stenosis.


Eligibility criteria:
inclusion criteria: 1. aged from 18 to 65; 2. diagnosed moderate/severe tracheal stenosis by chest ct and/or bronchoscopy; 3. difficulty breathing symptoms 4. agree to participate in this trial and sign the informed consent form. exclusion criteria: 1. those who were suffered from respiratory failure or more severe caused by dyspnea; 2. combined other serious systemic diseases (severe arrhythmia, acute myocardial ischemia, uncontrollable hypertension crisis, active gastric ulcer, uncontrolled diabetes, renal failure, blood system diseases or coagulation dysfunction); 3. those who were suffered from severe mental illness or could not take care of themselves; 4. pregnant or lactating women; 5. those who could not understand the trial procedures and correctly the trial equipment; 6. those who participated in other clinical trials in the first 3 months before the screening date. quit criteria 1. the subjects requiring emergency intubation or other intervention or surgical treatment due to worsened tracheal stenosis; 2. subjects who had severe adverse events during treatment; 3. subjects who did not want to continue to participate in the trial; 4. the subjects who were necessarily terminated for the trial by the investigators.

Keywords: tracheal stenosis, hydrogen generator, hydrogen-oxygen, dyspnea.
nabi-hb administered subcutaneously in patients with hepatitis b virus post liver transplantation

Conditions: Hepatitis B, Chronic

Summary: a phase 3, multicenter, open label study to assess the safety and efficacy of nabi-hb, administered subcutaneously in patients with hepatitis b virus associated liver disease who underwent liver transplantation.

this is a phase 3 prospective, single arm open label study to be conducted t approximately 4 study sited located in th e usa. approximately 25 hbv dna negative patients who underwent liver transplant at least one year prior, due to chronic hepatitis b infection will bwe eligible for study participation. the study consist of a total of 16 study visit and the duration of participation will be 20 weeks for each patients. patients will be converted from the intravenous standard hbig to nabi-hb subcutaneous administration according to the individual scheduled dosing interval.

Eligibility criteria:
inclusion criteria: * male or female patients 18 years old or older as of visit one. * if female is not trying to conserve, not lactating, and has a negative serum pregnancy test and use an acceptable method of contraception or be at least one year post-menopausal or surgically sterile. * able to provide written informed consent. * first time liver transplant recipient. * primary, single organ recipient (deceased donor \<65 years old). * receive regular long-term hbig prophylaxis with stabilized hbig dosage and administration intervals. * have negative quantifiable hbv-dna and hbsag results prior to dosing at visit 2. * following the last iv administration of hbig, have a baseline serum anti-hbs level of \>150 iu/ml prior to dosing at visit 2. exclusion criteria * positive hcv or hiv test results. * unexplained elevated liver function tests. * serum creatinine level \>2.0 times the upper limit of normal. * life expectancy \<6 months. * liver transplantation with ongoing acute rejection episode. donor liver that was from a hepatitis bor c positive donor. underwent a liver transplant \<12 months prior to visit 1. * know history of cancer, suspected cancer, or cancer therapy within 12 months. * history of autoimmune disease. * history/current evidence of coagulation disorder, severe cardiac disease, unhealed gastric or duodenal ulcer, or other significant disease. * evidence of any other unresolved infection and any unresolved opportunistic infection requiring treatment. * known immunoglobulin a deficiency. * history of use of immunosupressive or immunomodulatory drug within 3 month prior to visit 1. (except low dose glucocorticoid therapy, \<10 mg of prednisone or equivalent per day.) * received and investigational drug 30 days prior to visit 1. * use of plasma preparations or other immunoglobulins during the study. * know intolerance to proteins of human origin, immunoglobulin, or comparable products. * evidence of alcohol and/or drug abuse within 6 month of visit 2 or inability/unwillingness to abstain from alcohol for the duration of the study.

Keywords: chronic hepatitis b liver disease
treatment of vein stenosis or occlusion with the oblique stent

Conditions: Iliac Vein Stenosis; Iliac Vein Occlusion

Summary: to evaluate the safety and effectiveness of grency venous stent system in the treatment of iliac vein stenosis or occlusion.

the purpose of this study was to evaluate the safety and effectiveness of a new dedicated venous stent system (grency) in the treatment of iliac vein stenosis or occlusion. the grency stent system has a hybrid oblique self-expanding design, which allows precise positioning at the iliocaval confluence.

Eligibility criteria:
inclusion criteria: 1. subjects aged 18-80 years; 2. ceap clinical grade c \>=3; 3. iliac vein stenosis \>=50% or occlusion; 4. patients voluntarily sign informed consent and complete follow-up. exclusion criteria: 1. subjects in pregnancy or lactation; 2. renal insufficiency; 3. subjects are allergic to contrast agents and anesthetics; 4. subjects are allergic to nitinol; 5. the life expectancy of cancer patients is less than 1 year; 6. the length of the stent is expected to exceed the length of the inguinal ligament; 7. both sides of iliac vein stents were required; 8. long term bedridden or wheelchair patients; 9. the target vessel of the subject has been implanted into the iliac vein stent; 10. subjects have anticoagulant contraindications or are unable to receive long-term new oral anticoagulant therapy; 11. the investigator judged that the subjects had poor compliance and could not complete the clinical trial; 12. subjects are participating in clinical trials of other drugs or medical devices and have not yet completed the primary end point of the study.
early telemedicine training in patients with copd

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Summary: chronic obstructive pulmonary disease (copd) is a widespread disease that can have a major impact on the lives of individuals. an essential element in the treatment of copd is rehabilitation of which supervised training is an important part. however, not all individuals with severe copd can participate in the rehabilitation provided by hospitals and municipal training centres due to distance to the training venues and transportation difficulties. the aim of the feasibility study was to evaluate an individualised home based training and counselling programme via video conference to patients with severe copd after hospitalization with regard to safety, clinical outcomes, patients' perception, organisational aspects and economic aspects.


Eligibility criteria:
inclusion criteria: * severe and very severe copd (i.e. with an fev1 (forced expiratory volume in 1 second) value under 50% of the predicted value, an fev1/fvc (forced vital capacity) ratio \< 70%, mrc (medical research council dyspnoea scale) grade 3) * ≥40 years * hospitalization with exacerbation of copd * declined participation in the hospital based rehabilitation * participation in videoconference sessions with a nurse for one week immediately after discharge. exclusion criteria: * inability to communicate via telephone and computer * systolic bp \<100mm hg * x-rays of the thorax showing abnormalities suspicious of thoracic malignancy or lobar pneumonia * a diagnosis of cancer or recurrence of cancer within the last 5 years * hospitalization with septic shock, acute myocardial infarction (ami) or other serious medical conditions (e.g. kidney disorder) * heart failure (ef\<30%) * if the patient did not wish to participate.

Keywords: pulmonary rehabilitation training counselling telemedicine videoconference copd chronic disease internet.
the role of trimetazidine on right ventricle function in pulmonary arterial hypertension

Conditions: Precapillary Pulmonary Hypertension

Summary: the study will evaluate the effect of trimetazidine versus placebo in addition to standard pulmonary arterial hypertension regime on right ventricular function in pulmonary arterial hypertension patients.

right ventricular dysfunction is the worst mortality predictor in pulmonary arterial hypertension (pah). recent study has described that approximately 25% of pah patients will developed into right ventricular failure despite therapeutic reduction of pulmonary vascular resistance. subsequently, several studies have shown that fatty acid accumulation in right ventricle was inversely correlated with right ventricular function in pah patients. several pah animal studies have revealed that metabolic glucose oxidation impairment through increased aerobic glycolysis, mitochondrial dysfunction, and lipotoxicity play significant role in right ventricular failure. moreover, several pulmonary hypertension animal studies have demonstrated the benefit of partial fatty acid inhibitor such as trimetazidine on right ventricle function. it was hypothesize that trimetazidine improved right ventricular function through indirect effect of increased glucose oxidation by blocking the randle cycle. therefore, we hypothesize that trimetazidine can improve right ventricular function in pulmonary arterial hypertension patients.

Eligibility criteria:
inclusion criteria: * pre-capillary pulmonary hypertension patients assessed by right heart catheterization * signed informed consent exclusion criteria: * patient belonging to post-capillary, isolated post-capillary, or combined post -capillary and pre-capillary pulmonary hypertension according to 2015 esc/ers guidelines for the diagnosis and treatment of pulmonary hypertension. * moderate to severe chronic pulmonary obstructive disease * right ventricular ejection fraction \> 45% assessed by cardiac magnetic resonance. * documented left ventricular dysfunction with left ventricular ejection fraction \< 50% assessed by cardiac magnetic resonance. * severe renal impairment (serum creatinine \> 2.5 mg/dl, egfr \< 30ml/min/1.73 m\^2, or routine dialysis treatment). * malignant arrhythmia such as total atrioventricular block or ventricular fibrillation or unstable ventricular tachycardia. * patients who are receiving or have been receiving any investigational drugs within 1 month before the baseline visit * acute or chronic impairment (other than dyspnea) limiting the ability to comply with study requirements * psychotic, addictive or other disorder limiting the ability to provide informed consent or to comply with study requirements * females who are lactating or pregnant or those who plan to become pregnant during the study * known parkinson disease * known hypersensitivity to any of the drug formulation
effects of gh on body proportions and final height in x-linked hypophosphatemic rickets

Conditions: Hypophosphatemic Rickets; Growth Disorders; Somatropin Therapy

Summary: x-linked hypophosphatemic rickets (xlh) is characterized by rickets, disproportionate short stature, impaired renal phosphate reabsorption and vitamin d metabolism. despite oral phosphate and vitamin d treatment, most children with xlh demonstrate reduced adult height. the main objective of the study is to determine the beneficial effects of recombinant human growth hormone (rhgh) therapy on body proportions after 36 month in these patients. secondary objective is to monitor side effects of the therapy.


Eligibility criteria:
inclusion criteria: * tanner stages of puberty b1, g1 * body height \< 2,5 sds * growth velocity \< 75% * confirmed diagnosis of xlhr * conservative treatment for at least 1 year (phosphate, vitamin d) * informed consent, written agreement exclusion criteria: * growth hormone deficiency * hypothyreosis * severe rickets * severe physical deformities * severe hyperparathyreoidism * chronic renal failure * complex syndrome involving failure to thrive * chronic disease with failure to thrive * impairment of glucose tolerance * tanner stages of puberty greater than b1, g1 * medical history of malignancy * therapy with growth hormone, glucocorticoides, anabolica * attending another clinical trial

Keywords: x-linked dominant hypophosphatemic rickets growth disorders anthropometry human growth hormone
zevalin post-marketing surveillance for adequateness of image interpretation criteria in japan

Conditions: Non-Hodgkin's Lymphoma (NHL)

Summary: this study is a regulatory post-marketing surveillance of zevalin (ibritumomab tiuxetan) in japan. in-111 zevalin is, at first, injected to patient for gamma scan imaging to assess biodistribution of the zevalin. when the imaging shows no altered distribution, y-90 zevalin is injected to the patient for the actual treatment. the objective of this study is to assess appropriateness and necessity of revision of the standardized criteria for image interpretation of in-111 zevalin by comparing assessment by the investigator and the members of the committee for image interpretation of in-111 zevalin. a total 40 patients will be recruited.


Eligibility criteria:
inclusion criteria: * patients who received in-111 zevalin to verify that expected biodistribution is present. exclusion criteria: * patients who are contraindicated based on the product label.

Keywords: zevalin cd20+ non-hodgkin's lymphoma mantle cell lymphoma
radiation-induced toxicity in prostate cancer/ standard-follow-up program prostate

Conditions: Prostate Cancer

Summary: the goal is to gain insight in the development and course of the toxicity after a curative treatment of prostate cancer

all with curative intent treated prostate cancer patients will be enrolled in the sfp (standard follow-up programme). it also includes the post -operative adjuvant treatments and the patients with positive lymph nodes. patients will complete weekly questionnaires to score the patient -rated toxicity. biweekly patients are seen by the treating radiation oncologist and / or aios in which the physician -rated toxicity is scored. in the follow-up will always patient -rated toxicity and physician -rated toxicity can be determined. use of an sfp should yield a profit for the practitioner , such as the automatic generation of letters. this should apply to all sfps . quality of life and toxicity in patients will be completed on the touch-screen computers at fu visits.

Eligibility criteria:
inclusion criteria: * all curative treated patients with prostatecancer( with positive lymph nodes) * all patients who will be treated with rt( including post-operative, adjuvant treatments) * are willing to fill in toxicity and qol-questionnarys (qlq-pr25 en de qlq-c30) exclusion criteria: patients who are not willing to fill in toxicity and qol-questionnarys patients who will not get rt non-curative or palliative treated patients (with bone mestasis) non-prostate cancer-patients

Keywords: acute toxicity late toxicity quality of life since 2011(set-up sfp-prostate)
increasing colorectal cancer screening uptake with a patient navigator

Conditions: Colorectal Cancer

Summary: patients who receive tailored navigation (consisting of a letter and patient navigation services) and get screened will be significantly greater than the control group who receives treatment as usual. a majority of patients will opt for fecal occult blood testing (fobt)as one of their preferred tests, after undergoing the "patient navigator" intervention and that proportion will be significantly greater than the group who opt for fobt in the control group.

primary outcome measure: number of patients who receive a letter and patient navigation services and get screened compared to the control group. secondary outcome measures: proportion (%) of patients preferring fobt vs.colonoscopy; predictors of crc screening and screening preference. subjects: ambulatory patients (men-women aged 50 years and above) recruited from primary care practices at the group health centre, sault ste marie, ontario. all patients will be screened for eligibility and those who are eligible and agree to participate in the study will be randomized to either of the two study arms: intervention group or control group.

Eligibility criteria:
inclusion criteria: * average risk men and women aged 50 - 74 * unscreened - defined as no prior crc screening * under-screened - defined as no fobt screening within the last two years * no colonoscopy or barium enema screening within the last five years * willing to provide consent to participate in the study. exclusion criteria: * fobt within the last two years * colonoscopy within five years * barium enema within five years * flexible sigmoidoscopy within five years * bowel cancer.

Keywords: colorectal cancer screening 50 years or older
effectiveness of 5% dextrose water versus corticosteroid injection for pain management of sjd

Conditions: Sacroiliac Joint Dysfunction

Summary: the sacroiliac joint (sij) is identified as a potential origin of low back pain and referred pain to the lower limb, with a prevalence rate ranging from 7% to 30%. typically, sij pain manifests in the buttock and occasionally extends to the posterior aspect of the ipsilateral thigh, resembling pain originating from lumbar spine sources, such as the zygapophysial joints or intervertebral discs.

for sacroiliac joint dysfunction (sijd) by examining the comparative effectiveness of two distinct interventions: the innovative 5% dextrous water (d/w) solution and the conventional corticosteroid injection. with corticosteroids associated with well-documented side effects and concerns about long-term use, the exploration of 5% d/w is particularly timely and holds promise as a potentially safer alternative.

Eligibility criteria:
inclusion criteria: * persons with sij pain for at least 3 months exclusion criteria: * pregnancy or breastfeeding * history of allergy or people contra indicated to our dose * already received corticosteroid injection in last 3 months